📰 Lu Xianping News
Lu Xianping News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lu Xianping. Real-time updates on events, politics, business and more.
September 15, 2022
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with...
February 14, 2022
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1...
February 14, 2022
HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human immunodeficiency virus (HIV) with antiviral suppression. The objective of this study (ClinicalTrials.gov Identifier: NCT05129189) is to evaluate the...
December 1, 2021
/PRNewswire/ -- Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide...
December 1, 2021
/PRNewswire/ -- Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide...
December 16, 2020
Chipscreen and HISUN reach a strategic cooperation News provided by Share this article Share this article SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPSCREEN BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right...